Clinical Edge Journal Scan

Pregnancy and the risk of developing multiple sclerosis: Is there a link?


 

Key clinical point: Pregnancy may have a protective effect on the risk of developing multiple sclerosis (MS) in addition to a hypothesized reverse causality.

Major finding: Women with MS vs. women without any autoimmune disease were less likely to record the 18 pregnancy-related gynecological International Classification of Diseases 10th Revision codes, with strongest negative correlation observed for the supervision of normal pregnancy (adjusted P = 9.12 × 10 27) and high-risk pregnancy (adjusted P = 2.49 × 10 −12).

Study details: Findings are from a retrospective case-control study including women with newly diagnosed MS (n = 5720) and three control cohorts of women with newly diagnosed Crohn’s Disease (n = 6280), psoriasis (n = 26,729), and women without any of the three autoimmune diseases (n = 40,555).

Disclosures: The study was funded by European Union’s Horizon 2020 Research and Innovation Program, Hertie Foundation, and the Hans and Klementia Langmatz Stiftung, among others. B Hemmer declared serving on scientific advisory boards and receiving speaker honoraria and research funding from various sources. The other authors declared no conflicts of interest.

Citation: Gasperi C et al. Association of pregnancies with risk of multiple sclerosis. Mult Scler. 2022 (Mar 18). Doi: 10.1177/13524585221080542

Recommended Reading

The Enigma of MS Etiology: Find an Answer, Ask More Questions
ICYMI Multiple Sclerosis
Childhood abuse may increase risk of MS in women
ICYMI Multiple Sclerosis
MS: Fingolimod cessation safe if followed by prompt commencement of new therapy
ICYMI Multiple Sclerosis
PMS: pNfL could serve as biomarker for disability progression and drug response
ICYMI Multiple Sclerosis
Adverse childhood experiences associated with increased multiple sclerosis risk in women
ICYMI Multiple Sclerosis
Relapsing MS: Ofatumumab demonstrates superior benefit-risk profile than teriflunomide in RDTN patients
ICYMI Multiple Sclerosis
Multiple sclerosis: B-cell depleting therapies hinder nAb response following SARS-CoV-2 vaccination
ICYMI Multiple Sclerosis
Progression independent of relapse activity is a major cause of CDA in early relapsing MS
ICYMI Multiple Sclerosis
Maternal and infant outcomes in pregnant patients with MS treated with natalizumab
ICYMI Multiple Sclerosis
Patients with multiple sclerosis at an increased risk for cardiovascular diseases
ICYMI Multiple Sclerosis